ImmuPharma PLC and Simbec-Orion Group Limited recently announced a collaboration agreement for the execution of a Pivotal Phase III clinical study of ImmuPharma’s Lupuzorâ„¢, the company’s lead compound to treat Systemic Lupus Erythematosus, a chronic and life-threatening autoimmune disease. Lupuzor was granted Fast Track status by the Food and Drugs Administration (FDA); it…
A recent study conducted by a team of researchers from Taiwan found that patients with Systemic lupus erythematosus (SLE) who are treated with a specific dose of an antimalarial drug UCQ) are less prone to develop diabetes mellitus. However, those SLE patients that are threated with high-dose glucocorticoids are…
Researchers from St. Jude Children’s Research Hospital found that a protein involved in tumor formation suppression also plays a role in preventing autoimmune diseases and other problems through decelerating the immune response. The study was published in the Nature Immunology journal. The research team found that the tumor…
A team of researchers from Taiwan found that patients with systemic lupus erythematosus (SLE) have higher levels of T helper 17 cells than healthy controls, thus encouraging research in IL-17/IL-17R blockades as a potential treatment targets for SLE. The study entitled “Increased Th17 cells in flow…
Researchers at Brigham and Women’s Hospital in Boston, Massachusetts, discovered that systemic lupus erythematosus (SLE) has lower mortality rates in Asian and Hispanic patients when compared to Black, White or Native American patients. The study entitled “Racial/Ethnic Variation in All-Cause Mortality among U.S. Medicaid Recipients…
Systemic lupus erythematosus (SLE) is an immune multi-systemic autoimmune condition that mainly affects young women. Current evidence from population-based studies and randomized controlled trials indicated the onset of SLE and lupus flares is triggered by various environmental factors, such as cigarette smoke, alcohol, occupationally- and non-occupationally-related chemicals, ultraviolet light,…
23andMe, Inc., a personal genetics company that helps people better understand and benefit from the human genome, recently announced a new partnership with Pfizer Inc. that will give them access to 23andMe’s research platform, which includes data of the genotypes from more than 800,000 individuals that consented to enroll in the study. From this partnership and…
A national leader in lupus research and chief of Rheumatology at the Beth Israel Deaconess Medical Center (BIDMC) George Tsokos, MD, was recently awarded with two prestigious awards by the Lupus Foundation of America and the American College of Rheumatology (ACR) during the 2014 ACR Annual Scientific Meeting held in Boston.
Christopher Sjöwall from the Rheumatology/AIR Department of Clinical and Experimental Medicine at Linköping in Sweden and colleagues, evaluated the performance of the Systemic Lupus International Collaborating Clinics (SLICC) criteria created in 2012 (SLIC-12) in a European population of patients with systemic lupus erythematosus (SLE). The study…
The Kadmon Corporation’s Phase 2 oral drug, KD025, a potent, bio-available and highly selective inhibitor of ROCK2 (Rho-associated coiled-coiled kinase 2) that can be taken orally was designed as one of its priority candidates to treat lupus through the LRxL-STAT Lupus Drug Repositioning Initiative. The selection of the drug was presented at the annual American College…